Charalampos Tzempetzis

Charalampos Tzempetzis

Auto-generated profile, based on publicly available information

Charalampos Tzempetzis

Penteli's Children Hospital

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2026 in Journal of Child Neurology
Verified
Journal Article
Closed access
CTCharalampos Tzempetzis
Charalampos Tzempetzis
CTChrysanthi Tsimakidi
Chrysanthi Tsimakidi
ETEirini Topoulli
Eirini Topoulli
DGDionysia Gkougka
Dionysia Gkougka
MGMaria Gontika
Maria Gontika
Background: Juvenile myasthenia gravis (JMG) is a rare autoimmune disorder with limited pediatric evidence and treatment extrapolated from adults. Seronegative disease complicates diagnosis, whereas prolonged corticosteroid use frequently results in substantial toxicity, highlighting the need for steroid-sparing therapies. Although adult studies support the efficacy of efgartigimod alfa, its role in pediatric and seronegative disease remains uncertain. Methods: We present a case of triple-seronegative JMG successfully treated with efgartigimod alfa, accompanied by a focused literature review of current diagnostic and therapeutic challenges. Results: A female adolescent with aggressive generalized JMG refractory to corticosteroids and intravenous immunoglobulin. Efgartigimod produced rapid, sustained clinical improvement, enabling corticosteroid tapering, and was well tolerated. This review contextualizes these findings within the evolving evidence for diagnosis and FcRn-targeted therapy in JMG. Conclusions: This case-based review highlights the diagnostic complexity of seronegative JMG and supports further evaluation of FcRn-targeted therapy in pediatric patients.